Showing 291-300 of 1718 results for "".
- New Drug Application Is Submitted for Vamorolone for Treating Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-drug-application-is-submitted-for-vamorolone-for-treating-duchenne-muscular-dystrophy/2470058/The submission of a new drug application (NDA) to the Food and Drug Administration (FDA) has been completed, seeking priority review for vamorolone (Santhera Pharmaceuticals, Prattein, Switzerland; and ReveraGen BioPharma, Rockville, MD) for the treatment of Duchenne muscular dystrophy (DMD).&nbs
- Phenogroups of Migraine Identified With Artificial Intelligence-Guided Topologic Mappinghttps://practicalneurology.com/news/phenogroups-of-migraine-identified-with-artificial-intelligence-guided-topologic-mapping/2469941/Migraine is increasingly as a as a heterogeneous disorder, with a wide variety of headache characteristics, associated symptoms, and treatment responses. In a study presented at the American Headache Society meeting in Denver, CO June 9-12, 2022, Chia-Chun Chiang, MD, senior assoc
- Quest for Alzheimer Disease Treatments Continueshttps://practicalneurology.com/news/quest-for-alzheimer-disease-treatments-continues/2469577/The quest for effective treatment of Alzheimer disease (AD) continues as phase 2B and 3 clinical trials meet major milestones. Enrollment is complete for a trial of once-daily low dose of the antiseizure medication levetiracetam (AGB101; AgeneBio, Baltimore, MD) for treatment of a
- FDA Approves Casimersen for Duchenne Muscular Dystrophy Amenable to Exon 45 Skippinghttps://practicalneurology.com/news/fda-approves-casimersen-for-duchenne-muscular-dystrophy-amenable-to-exon-45-skipping/2469512/The Food and Drug Administration (FDA) granted approval for casimersen (Amondys 45; Sarepta Therapeutics, Silver Spring, MD) for treatment of Duchenne muscular dystrophy (DMD) caused by a dystrophin mutation amenable to exon 45 skipping. Casinmersen is an antisense oligonucleotide that blocks exo
- FDA Gives Market Clearance for Muscle Stimulator to Reduce Snoring and Mild Obstructive Sleep Apneahttps://practicalneurology.com/news/fda-gives-market-clearance-for-muscle-stimulator-to-reduce-snoring-and-mild-obstructive-sleep-apnea/2469494/The Food and Drug Administration (FDA) authorized a prescription-only device (eXciteOSA; Signifier Medical Technologies, Silver Spring, MD) to reduce snoring and mild obstructive sleep apnea. The device is used when the individuals is awake to improve tongue muscle function. FDA a
- New Genetic Tests Available for Hereditary Ataxiashttps://practicalneurology.com/news/new-genetic-tests-available-for-hereditary-ataxias/2469486/Several genetic tests, including repeat-expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxia have been newly made available by GeneDx (Gaithersberg, MD). The repeat-expansion analysis may be done concurrently with single nucleotide va
- Update on Migraine Incidence and Risk for Progression from Episodic to Chronic Migrainehttps://practicalneurology.com/news/update-on-migraine-incidence-of-migraine-and-risk-for-progression-from-episodic-to-chronic-migraine/2469439/At the Virtual Scottsdale Headache Symposium 2020, Richard Lipton, MD presented the latest data from epidemiology studies of migraine. Dr. Lipton noted that epidemiologic studies not only provide a conceptual model of the disease and approaches for better understanding but also help to assess and
- Posttraumatic Headache Management Update from Virtual Scottsdale Headache Symposium 2020https://practicalneurology.com/news/posttraumatic-headache-management-update-from-virtual-scottsdale-headache-symposium-2020/2469438/At the Virtual Scottsdale Headache Symposium 2020 held on November 21st, 2020, Dr. Juliana VanderPluym, MD, FAHS of the Mayo clinic reviewed current knowledge on management of posttraumatic headache, providing a step-by-step approach as follows below. 1. Posttraumatic headache is
- Teens with Epilepsy Are More Likely to Discuss Suicide Onlinehttps://practicalneurology.com/news/teens-with-epilepsy-are-more-likely-to-discuss-suicide-online/2469098/Results of a study presented at the American Epilepsy Society Annual Meeting December 6-10, 2019 in Baltimore, MD show that teens with epilepsy are more than twice as likely as adults with the condition to talk about suicide online. The data suggests that teens are concerned with the unknown aspe
- Women with Epilepsy Are Less Likely to Breastfeed Their Newbornshttps://practicalneurology.com/news/women-with-epilepsy-are-less-likely-to-breastfeed-their-newborns/2469096/Findings from 2 clinical studies presented at the American Epilepsy Society Annual Meeting, December 6-10 in Baltimore, MD show that women with epilepsy are less likely to breastfeed their newborns than new mothers without epilepsy. Support from neurologists and lactation consultants, however, ca